News ESMO26: Sac-TMT delivers the goods in PD-L1-negative NSCLC Kelun and MSD's TROP2-directed ADC, sac-TMT, reduced the risk of disease progression or death by 51% when used first-line in PD-L1-negative NSCLC.
News ESMO26: Bayer's Nubeqa finds new prostate cancer role Bayer's prostate cancer drug Nubeqa has reduced the risk of the disease spreading or death by 58% in patients at high risk of disease recurrence.
News ESMO26: 'Unprecedented' results from DeLLphi-305 in SCLC Amgen has revealed data that it hopes will move its DLL3-targeting T-cell engager Imdelltra into the first-line setting in small cell lung cancer.
News ESMO26: VOLGA stirs up perioperative bladder cancer therapy The VOLGA trial shows that Imfinzi and Padcev could be a rival Keytruda+Padcev in perioperative treatment of muscle-invasive bladder cancer.
News ESMO26: Lilly's sofe-m ADC stakes a claim in ovarian cancer Eli Lilly's first major readout at ESMO comes from a phase 1 trial of its FRα-targeting sofe-m in platinum-sensitive ovarian cancer (PSOC).
News ESMO26: Evidence for GSK's mo-rez builds in ovarian cancer New data from GSK's BEHOLD-1 study of B7-H4-targeted ADC mo-rez reinforces earlier results in platinum-resistant ovarian cancer.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.